ZIP1 Antibody
| Code | Size | Price |
|---|
| PSI-6081-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6081-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
ZIP1 Antibody: ZIP1, ZIRTL, IRT1, ZIP1, CGI-08, CGI-71, Zinc transporter ZIP1, Solute carrier family 39 member 1, ZIP-1
Application Note:
ZIP1 antibody can be used for detection of ZIP1 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
ZIP1 Antibody: ZIP1, also known as ZIRTL (zinc-iron regulated transporter-like), is the first mammalian member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. ZIP1 expression is markedly downregulated in a number of cancerous tissues and is thought to function as a tumor suppressor gene in prostate cancer. More recent studies have shown that overexpression of ZIP1 and concomitant increased levels of intracellular zinc in PC-3 cells cause a significant inhibition of NF-κB, leading to down-regulation of the antiapoptotic protein Bcl-2, Bcl-XL, and the apoptosis inhibitor XIAP, reducing the malignant potential of prostate cancer cells in vitro and in vivo.
Background References:
- Lioumi M, Ferguson CA, Sharpe PT, et al. Isolation and characterization of human and mouse ZIRTL, a member of the IRT1 family of transporters, mapping within the epidermal differentiation complex. Genomics 1999; 62:272-80.
- Eide DJ. The SLC39 family of metal ion transporters. Pflugers Arch. 2004; 447:796-800.
- Taylor KM and Nicohlson RI. The LZT proteins; the LIV-1 subfamily of zinc transporters. Biochim. Biophys. Acta. 2003; 1611:16-30.
- Costello LC and Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol. Cancer. 2006; 5:17.
Buffer:
ZIP1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (88%)
Immunogen:
ZIP1 antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human ZIP1.
The immunogen is located within amino acids 40 - 90 of ZIP1.
The immunogen is located within amino acids 40 - 90 of ZIP1.
NCBI Gene ID #:
27173
NCBI Official Name:
solute carrier family 39 (zinc transporter), member 1
NCBI Official Symbol:
SLC39A1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 13, 36 kDa
Observed: 38 kDa
Observed: 38 kDa
Protein Accession #:
NP_055252
Protein GI Number:
21361423
Purification:
ZIP1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
At least two isoforms of ZIP1 are known to exist; this antibody will detect both isoforms. ZIP1 antibody is predicted not to cross-react with other ZIP family proteins.
Swissprot #:
Q9NY26
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | ZIP1 Peptide | PSI-6081P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|